Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 20, 2024

Unesbulin Plus Dacarbazine for Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma
J. Clin. Oncol 2024 Apr 29;[EPub Ahead of Print], BA Van Tine, MA Ingham, S Attia, CF Meyer, JD Baird, E Brooks-Asplund, D D'Silva, R Kong, A Mwatha, K O'Keefe, M Weetall, R Spiegel, GK Schwartz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading